{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T06:09:32Z","timestamp":1767852572541,"version":"3.49.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T00:00:00Z","timestamp":1673654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T00:00:00Z","timestamp":1673654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National Institute of Aging","award":["1K76AG074923-01"],"award-info":[{"award-number":["1K76AG074923-01"]}]},{"DOI":"10.13039\/100002192","name":"LUNGevity Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002192","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s00262-023-03373-y","type":"journal-article","created":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T13:04:34Z","timestamp":1673701474000},"page":"1727-1735","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Association between pre-treatment chest imaging and pulmonary function abnormalities and immune checkpoint inhibitor pneumonitis"],"prefix":"10.1007","volume":"72","author":[{"given":"Alex","family":"Wong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Riley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Songzhu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing Gennie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vince","family":"Esguerra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingjia","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabrielle","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory A.","family":"Otterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kari","family":"Kendra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn J.","family":"Presley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lai","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dwight H.","family":"Owen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9803-4465","authenticated-orcid":false,"given":"Kevin","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,1,14]]},"reference":[{"key":"3373_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17670-y","author":"C Robert","year":"2020","unstructured":"Robert C (2020) A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun. https:\/\/doi.org\/10.1038\/s41467-020-17670-y","journal-title":"Nat Commun"},{"issue":"8","key":"3373_CR2","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1002\/eji.201847659","volume":"49","author":"A Tanaka","year":"2019","unstructured":"Tanaka A, Sakaguchi S (2019) Targeting treg cells in cancer immunotherapy. Eur J Immunol 49(8):1140\u20131146","journal-title":"Eur J Immunol"},{"issue":"19","key":"3373_CR3","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG et al (2016) Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med 375(19):1823\u20131833","journal-title":"N Engl J Med"},{"issue":"2","key":"3373_CR4","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1302369","volume":"369","author":"JD Wolchok","year":"2013","unstructured":"Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM (2013) Nivolumab plus Ipilimumab in advanced melanoma. N Engl J Med 369(2):122\u2013133","journal-title":"N Engl J Med"},{"issue":"14","key":"3373_CR5","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer RJ, Tannir NM, McDermott DF, Aren Frontera O, Melichar B, Choueiri TK (2018) Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med 378(14):1277\u20131290","journal-title":"N Engl J Med"},{"issue":"2","key":"3373_CR6","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1002\/cpt.1597","volume":"107","author":"S Yang","year":"2019","unstructured":"Yang S, Yu KH, Palmer N, Fox K, Kou SC, Kohane IS (20ol19) Autoimmune effects of lung cancer immunotherapy revealed by data-driven analysis on a nationwide cohort. Clin Pharmacol Ther 107(2):388\u2013396","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"3373_CR7","doi-asserted-by":"publisher","first-page":"e000356","DOI":"10.1136\/jitc-2019-000356","volume":"8","author":"P Boland","year":"2020","unstructured":"Boland P, Pavlick AC, Weber J, Sandigursky S (2020) Immunotherapy to treat malignancy in patients with pre-existing autoimmunity. J Immunother Cancer 8(1):e000356","journal-title":"J Immunother Cancer"},{"issue":"05","key":"3373_CR8","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1055\/s-0036-1592298","volume":"37","author":"J Naidoo","year":"2016","unstructured":"Naidoo J, Naidoo J, Brahmer JR (2016) Immunotherapy for lung cancer: no longer an abstract concept. Semin Respir Crit Care Med 37(05):771\u2013782","journal-title":"Semin Respir Crit Care Med"},{"issue":"12","key":"3373_CR9","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1001\/jamaoncol.2016.2453","volume":"2","author":"M Nishino","year":"2016","unstructured":"Nishino M, Giobbie-Hurder A, Hatabu H, Ramaiya NH, Hodi FS (2016) Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer a systematic review and meta-analysis. JAMA Oncol 2(12):1607\u20131616","journal-title":"JAMA Oncol"},{"key":"3373_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/srep44173","author":"J Wu","year":"2017","unstructured":"Wu J, Hong D, Zhang X, Lu X, Miao J (2017) PD-1 inhibitors increase the incidence and risk of pneumonitis in cancer patients in a dose-independent manner: a meta-analysis. Sci Rep. https:\/\/doi.org\/10.1038\/srep44173","journal-title":"Sci Rep"},{"key":"3373_CR11","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.lungcan.2018.10.001","volume":"125","author":"T Yamaguchi","year":"2018","unstructured":"Yamaguchi T, Shimizu J, Hasegawa T, Horio Y, Inaba Y, Yatabe Y (2018) Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: a retrospective analysis. Lung cancer Amsterdam Netherlands 125:212\u2013217","journal-title":"Lung cancer Amsterdam Netherlands"},{"issue":"12","key":"3373_CR12","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1016\/j.jtho.2018.08.2035","volume":"13","author":"K Suresh","year":"2018","unstructured":"Suresh K, Voong KR, Shankar B et al (2018) Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors. J Thorac Oncol 13(12):1930\u20131939","journal-title":"J Thorac Oncol"},{"issue":"3","key":"3373_CR13","doi-asserted-by":"publisher","first-page":"599","DOI":"10.20892\/j.issn.2095-3941.2020.0102","volume":"17","author":"X Zhai","year":"2020","unstructured":"Zhai X, Zhang J, Tian Y et al (2020) The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients. Cancer Biol Med 17(3):599\u2013611","journal-title":"Cancer Biol Med"},{"issue":"7","key":"3373_CR14","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","volume":"35","author":"J Naidoo","year":"2017","unstructured":"Naidoo J, Wang X, Woo KM, Iyriboz T, Halpenny D, Cunningham J (2017) Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy. J Clin Oncol 35(7):709\u2013717","journal-title":"J Clin Oncol"},{"issue":"2","key":"3373_CR15","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.chest.2017.04.177","volume":"152","author":"M Khunger","year":"2017","unstructured":"Khunger M, Rakshit S, Pasupuleti V, Hernandez AV, Mazzone P, Stevenson J (2017) Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in\u00a0non-small cell\u00a0lung\u00a0cancer. Chest 152(2):271\u2013281","journal-title":"Chest"},{"issue":"20","key":"3373_CR16","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia SJ, Villegas A, Daniel D et al (2017) Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med 377(20):1919\u20131929","journal-title":"N Engl J Med"},{"issue":"11","key":"3373_CR17","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.22906","volume":"3","author":"K Shimoji","year":"2020","unstructured":"Shimoji K, Masuda T, Yamaguchi K et al (2020) Association of preexisting interstitial lung abnormalities with immune checkpoint inhibitor-induced interstitial lung disease among patients with nonlung cancers. JAMA Netw Open 3(11):e2022906","journal-title":"JAMA Netw Open"},{"issue":"7","key":"3373_CR18","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/1759-7714.12759","volume":"9","author":"O Kanai","year":"2018","unstructured":"Kanai O, Kim YH, Demura Y, Kanai M, Ito T, Fujita K (2018) Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease Nivolumab in patients with ILD. Thoracic Cancer 9(7):847\u2013855","journal-title":"Thoracic Cancer"},{"issue":"8","key":"3373_CR19","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/j.jtho.2020.04.002","volume":"15","author":"Y Suzuki","year":"2020","unstructured":"Suzuki Y, Karayama M, Uto T et al (2020) Assessment of Immune-Related Interstitial Lung Disease in Patients With NSCLC Treated with Immune Checkpoint Inhibitors: A Multicenter Prospective Study. J Thorac Oncol 15(8):1317\u20131327","journal-title":"J Thorac Oncol"},{"issue":"6","key":"3373_CR20","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1164\/rccm.201906-1202ST","volume":"200","author":"CR Sears","year":"2019","unstructured":"Sears CR, Peikert T, Possick JD, Naidoo J, Nishino M, Patel SP (2019) Knowledge gaps and research priorities in immune checkpoint inhibitor-related pneumonitis an official American thoracic society research statement. Am J Respir Crit care Med 200(6):31\u201343","journal-title":"Am J Respir Crit care Med"},{"issue":"1","key":"3373_CR21","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13014-018-1030-1","volume":"13","author":"F Li","year":"2018","unstructured":"Li F, Zhou Z, Wu A et al (2018) Preexisting radiological interstitial lung abnormalities are a risk factor for severe radiation pneumonitis in patients with small-cell lung cancer after thoracic radiation therapy. Radiat Oncol 13(1):82","journal-title":"Radiat Oncol"},{"issue":"10","key":"3373_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0140437","volume":"10","author":"Y Ozawa","year":"2015","unstructured":"Ozawa Y, Abe T, Omae M et al (2015) Impact of preexisting interstitial lung disease on acute, extensive radiation pneumonitis: retrospective analysis of patients with lung cancer. PLoS ONE 10(10):e0140437","journal-title":"PLoS ONE"},{"issue":"2","key":"3373_CR23","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG (2009) Research electronic data capture (REDCap) a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inf 42(2):377\u2013381","journal-title":"J Biomed Inf"},{"key":"3373_CR24","doi-asserted-by":"publisher","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O\u2019Neal L (2019) The REDCap consortium: building an international community of software platform partners. J Biomed Inf 95:103208","journal-title":"J Biomed Inf"},{"issue":"11","key":"3373_CR25","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1007\/s00262-020-02674-w","volume":"69","author":"M Li","year":"2020","unstructured":"Li M, Spakowicz D, Zhao S et al (2020) Brief report: inhaled corticosteroid use and the risk of checkpoint inhibitor pneumonitis in patients with advanced cancer. Cancer Immunol Immunother CII 69(11):2403\u20132408","journal-title":"Cancer Immunol Immunother CII"},{"issue":"12","key":"3373_CR26","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1001\/jamaoncol.2020.5012","volume":"6","author":"B Shankar","year":"2020","unstructured":"Shankar B, Zhang J, Naqash AR et al (2020) Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer. JAMA Oncol 6(12):1952\u20131956","journal-title":"JAMA Oncol"},{"issue":"8","key":"3373_CR27","doi-asserted-by":"publisher","first-page":"e70","DOI":"10.1164\/rccm.201908-1590ST","volume":"200","author":"BL Graham","year":"2019","unstructured":"Graham BL, Steenbruggen I, Miller MR, Barjaktarevic IZ, Cooper BG, Hall GL (2019) Standardization of spirometry 2019 update an official American thoracic society and european respiratory society technical statement. Am J Respir Crit Care Med 200(8):e70\u2013e88","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"3373_CR28","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1183\/09031936.04.00017104","volume":"23","author":"PJ Sterk","year":"2004","unstructured":"Sterk PJ (2004) Lets not forget: the GOLD criteria for COPD are based on post-bronchodilator FEV1. Eur Respir J 23(4):497\u2013498","journal-title":"Eur Respir J"},{"key":"3373_CR29","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ejca.2015.10.015","volume":"53","author":"M Nishino","year":"1990","unstructured":"Nishino M, Brais LK, Brooks NV, Hatabu H, Kulke MH, Ramaiya NH (1990) Drug-related pneumonitis during mammalian target of rapamycin inhibitor therapy in patients with neuroendocrine tumors: a radiographic pattern-based approach. Eur J Cancer 53:163\u2013170","journal-title":"Eur J Cancer"},{"issue":"12","key":"3373_CR30","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1164\/rccm.200710-1501OC","volume":"177","author":"S Kudoh","year":"2008","unstructured":"Kudoh S, Kato H, Nishiwaki Y, Fukuoka M, Nakata K, Ichinose Y (2008) Interstitial lung disease in Japanese patients with lung cancer a cohort and nested case-control study. Am J Respir Crit Care Med 177(12):1348\u20131357","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"3373_CR31","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.chest.2018.12.011","volume":"155","author":"A Adegunsoye","year":"2019","unstructured":"Adegunsoye A, Vij R, Noth I (2019) Integrating Genomics Into Management of\u00a0Fibrotic Interstitial Lung Disease. Chest 155(5):1026\u20131040","journal-title":"Chest"},{"key":"3373_CR32","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3389\/fmed.2018.00043","volume":"5","author":"O Desai","year":"2018","unstructured":"Desai O, Winkler J, Minasyan M, Herzog EL (2018) The Role of Immune and Inflammatory Cells in Idiopathic Pulmonary Fibrosis. Front Med (Lausanne) 5:43","journal-title":"Front Med (Lausanne)"},{"issue":"10","key":"3373_CR33","doi-asserted-by":"publisher","first-page":"4305","DOI":"10.1172\/JCI128654","volume":"129","author":"K Suresh","year":"2019","unstructured":"Suresh K, Naidoo J, Zhong Q et al (2019) The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis. J Clin Invest 129(10):4305\u20134315","journal-title":"J Clin Invest"},{"issue":"10","key":"3373_CR34","volume":"2","author":"JE Reuss","year":"2021","unstructured":"Reuss JE, Brigham E, Psoter KJ et al (2021) Pretreatment Lung Function and Checkpoint Inhibitor Pneumonitis in NSCLC. JTO Clin Res Rep 2(10):100220","journal-title":"JTO Clin Res Rep"},{"issue":"1","key":"3373_CR35","first-page":"109","volume":"108","author":"JB Orens","year":"1995","unstructured":"Orens JB, Kazerooni EA, Martinez FJ et al (1995) The sensitivity of high-resolution CT in detecting idiopathic pulmonary fibrosis proved by open lung biopsy. A prospective study. Chest. 108(1):109\u2013115","journal-title":"A prospective study. Chest."},{"issue":"1","key":"3373_CR36","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3949\/ccjm.68.1.33","volume":"68","author":"KR Flaherty","year":"2001","unstructured":"Flaherty KR, Martinez FJ (2001) Diagnosing interstitial lung disease: a practical approach to a difficult problem. Cleve Clin J Med 68(1):33\u201334","journal-title":"Cleve Clin J Med"},{"issue":"7","key":"3373_CR37","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1001\/archdermatol.2010.134","volume":"146","author":"PA Morganroth","year":"2010","unstructured":"Morganroth PA, Kreider ME, Okawa J et al (2010) Interstitial lung disease in classic and skin-predominant dermatomyositis: a retrospective study with screening recommendations. Arch Dermatol 146(7):729\u2013738","journal-title":"Arch Dermatol"},{"key":"3373_CR38","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.3389\/fonc.2020.01785","volume":"10","author":"S Zhu","year":"2020","unstructured":"Zhu S, Fu Y, Zhu B, Zhang B, Wang J (2020) Pneumonitis Induced by Immune Checkpoint Inhibitors: From Clinical Data to Translational Investigation. Front Oncol 10:1785","journal-title":"Front Oncol"}],"updated-by":[{"DOI":"10.1007\/s00262-023-03391-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,2,18]],"date-time":"2023-02-18T00:00:00Z","timestamp":1676678400000}}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-023-03373-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-023-03373-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-023-03373-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T15:05:04Z","timestamp":1684508704000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-023-03373-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,14]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["3373"],"URL":"https:\/\/doi.org\/10.1007\/s00262-023-03373-y","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00262-023-03391-w","asserted-by":"object"}]},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,14]]},"assertion":[{"value":"4 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00262-023-03391-w","URL":"https:\/\/doi.org\/10.1007\/s00262-023-03391-w","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Otterson serves as a consultant on the Data Safety Monitoring Board on Beigene and Novocure. The remaining authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"The study protocol was reviewed and approved by the Ohio State Institutional Review Board (2016C0070), and a waiver of informed consent was granted due to the retrospective nature of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}